Tag Archives: CEEU

Cardinal among 10 indicted by Vatican for financial crimes

  • Pope approved move against cardinal, who says he is innocent
  • Former head of Vatican Financial Intelligence denies charges
  • Becciu most senior Vatican official charged with financial crime
  • Trial to start July 27

VATICAN CITY, July 3 (Reuters) – A prominent Italian cardinal was among 10 people sent to trial in the Vatican on Saturday charged with financial crimes including embezzlement, money laundering, fraud, extortion and abuse of office.

Cardinal Angelo Becciu, formerly a senior official in the Vatican administration, as well as two top officials at the Vatican’s Financial Intelligence Unit will go on trial on July 27 over a multi-million euro scandal involving the Vatican’s purchase of a building in one of London’s smartest districts.

The trial will inevitably bring a swirl of media interest to the tiny city-state surrounded by Rome, and appears to underscore Pope Francis’ determination to cure the rot in Vatican finances, even if it involves messy public hearings.

Becciu, 73, whom the pope fired from his senior clerical post last year for alleged nepotism, and who has always maintained his innocence during a two-year investigation, becomes the most senior Vatican official to be charged with financial crimes.

The pope personally gave the required approval last week for Becciu to be indicted, according to a 487-page indictment request seen by Reuters. The Vatican announced the indictments in a two-page statement.

The charges against Becciu include embezzlement and abuse of office. An Italian woman who worked for him was charged with embezzlement and the cardinal’s former secretary, a priest, was accused of extortion.

Becciu said in a statement that he was a victim of a “machination” and reaffirmed his “absolute innocence”.

Two Italian brokers, Gianluigi Torzi and Raffaele Mincione, were charged with embezzlement, fraud and money laundering. Torzi, for whom Italian magistrates issued an arrest warrant in April, was also charged with extortion.

There was no immediate response to attempts to reach their lawyers, but both men have consistently denied wrongdoing.

Four companies associated with individual defendants, two in Switzerland, one in the United States and one in Slovenia, were also indicted, according to the document.

POLICE RAID

The investigation into the purchase of the building became public on Oct. 1, 2019, when Vatican police raided the offices of the Secretariat of State, the administrative heart of the Catholic Church, and those of the Vatican’s Financial Information Authority (AIF).

The then-president of the AIF, Rene Bruelhart, a 48-year-old Swiss, and AIF’s former Italian director, Tommaso Di Ruzza, 46, were charged with abuse of office for allegedly failing to adequately protect the Vatican’s interests and giving Torzi what the indictment request called an “undue advantage”.

Di Ruzza was also accused of embezzlement related to alleged inappropriate use of his official credit card, and of divulging confidential information.

Bruelhart said in a text message that he had “always carried out my functions and duties with correctness” and that “the truth about my innocence will emerge.”

Di Ruzza did not immediately respond to a voicemail requesting comment.

In 2014, the Secretariat of State invested more than 200 million euros, much of it from contributions from the faithful, in a fund run by Mincione, securing about 45% of a commercial and residential building at 60 Sloane Avenue in London’s South Kensington district.

The indictment request said Mincione had tried to deceive the Vatican, which in 2018 tried to end the relationship.

It turned to Torzi for help in buying up the rest of the building, but later accused him of extortion.

‘ENORMOUS LOSSES’

At the time, Becciu was in the last year of his post as deputy secretary of state for general affairs, a powerful administrative position that handles hundreds of millions of euros.

All told, the Secretariat of State sank more than 350 million euros into the investment, according to Vatican media, and suffered what Cardinal George Pell, the former Vatican treasurer, told Reuters last year were “enormous losses”.

Torzi was arrested in the Vatican in June 2020, and spent a week in custody.

According to the indictment request, Becciu is charged with five counts of embezzlement, two of abuse of office, and one count of inducing a witness to perjury. About 75 pages of the document are dedicated to Becciu.

It says Becciu tried to “heavily deflect” the inquiry into Vatican investments, including the London building, and tried to discredit the investigating magistrates via the Italian media.

Becciu continued to have influence over money transfers at the Secretariat even after he left the post, the document said.

The main charges against Becciu involve the alleged funnelling of money and contracts to companies or charitable organisations controlled by his brothers on their native island of Sardinia.

Another Sardinian, Cecilia Maronga, 40, who worked for Becciu, was charged with embezzlement. Her cellphone was not connected.

The indictment request said she had received about 575,000 euros from the Secretariat of State in 2018-2019.

She has said on Italian television that the money, sent to her company in Slovenia, was to ransom kidnapped missionaries in Africa. But the indictment request said much of it was used for “personal benefit”, including the purchase of luxury goods.

Reporting by Philip Pullella; Editing by Kevin Liffey

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Germany could ease travel curbs as Delta variant takes over

People walk past a colonnade on Museum Island during warm temperatures, amid the coronavirus disease (COVID-19) pandemic, in Berlin, Germany May 30, 2021. REUTERS/Annegret Hilse

BERLIN, July 1 (Reuters) – Germany expects the Delta variant of COVID-19 to account for up to 80% of infections this month and could ease travel restrictions from countries like Portugal and Britain where it already dominates, its health minister said on Thursday.

Jens Spahn told a news conference that Germany could reduce the current 14-day quarantine requirement that it imposes on travellers from countries with high levels of the Delta variant once it is sure that vaccinated people are protected.

Spahn said the move could happen soon, without specifying.

Germany’s STIKO vaccination commission said later on Thursday that UK studies show that two vaccines doses seem to provide as much protection against the Delta variant as against other COVID-19 variants. read more

Spahn reiterated the importance of speeding up vaccinations, noting that 37% of Germany’s population has now received two shots, while 55% has had a first dose.

About half of German coronavirus cases are currently Delta variant and Spahn said it will dominate later this month.

Germany last week declared Portugal and Russia to be “virus-variant zones”, meaning only German residents can enter the country from those countries and still face a mandatory two-week quarantine even if they are fully vaccinated or test negative.

That had prompted German tourists there to rush home and airlines to cancel flights.

Germany also classifies Britain as such a “virus variant” zone. Chancellor Angela Merkel is due to discuss travel restrictions when she meets British Prime Minister Boris Johnson on Friday.

Spahn suggested these countries could be shifted to a designation as risk areas, meaning people can travel if they are fully vaccinated or have recovered from COVID-19, or be released from quarantine after five days if they test negative.

The European Commission said on Tuesday that Germany should not impose a travel ban on Portugal but limit itself to imposing testing and quarantine requirements to be in line with the European Union approach meant to ease summer travel.

Reporting by Emma Thomasson and Thomas Escritt; Editing by Maria Sheahan and Catherine Evans

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman

June 30 (Reuters) – CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago.

The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected.

CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that new variants had proved a headwind, denting investor confidence in its ability to take on rival shots.

That wiped billions of euros from its market value.

Wednesday’s news sent U.S.-listed shares of the company 10.2% lower to $66 after the bell.

Late-stage trials of BioNTech/Pfizer (22UAy.DE), (PFE.N) and Moderna (MRNA.O) vaccines, which like CureVac’s are based on mRNA technology, had efficacy rates of well above 90% across all age groups but took place when the original version of the coronavirus was dominant.

Data on their products have, however, so far suggested only somewhat weaker protection against new variants.

The CureVac study, which involved about 40,000 adult volunteers in Europe and Latin America, showed that efficacy was 77% in the age group below 60 years of age when considering only moderate to severe symptoms and excluding mild cases.

CureVac said it had sent the data to the European Medicines Agency (EMA) as part of an ongoing dialogue with the EU drugs regulator.

CureVac previously said that the regulatory hurdle was 50% efficacy in principle but that various other considerations would come into play.

“In this final analysis, CVnCoV demonstrates a strong public health value in fully protecting study participants in the age group of 18 to 60 against hospitalization and death and 77% against moderate and severe disease – an efficacy profile, which we believe will be an important contribution to help manage the COVID-19 pandemic and the dynamic variant spread,” said Chief Executive Officer Franz-Werner Haas.

CureVac had registered 228 infections overall for the final analysis, after 134 cases for the interim analysis.

Public health representatives across the globe are pushing for a fast deployment of available vaccines to counter highly contagious mutations of COVID-19 such as the Delta variant that first emerged in India.

The EMA has said it would not impose a 50% efficacy threshold for vaccines and that full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot. read more

Under CureVac’s only major supply deal for the product tested in the trial, the European Union secured up to 405 million doses of the vaccine in November, of which 180 million are optional.

In a bet on CureVac’s technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial. read more

CureVac had lined up a network of manufacturing partners including Celonic Group of Switzerland, Novartis (NOVN.S), Bayer (BAYGn.DE), Fareva, Wacker (WCHG.DE) and Rentschler Biopharma SE.

($1 = 0.8377 euros)

Reporting by Ludwig Burger, Editing by Rosalba O’Brien

Our Standards: The Thomson Reuters Trust Principles.

Read original article here